Plerixafor is a CXCR4 inhibitor that is able to increase the mobilization of PBSC in combination with G-CSF compared with G-CSF alone. 1, 2 In patients who had failed a previous mobilization attempt the success rate of plerixafor þ G-CSF was about 60-80%. 3, 4 Lymphoma patients who already failed X1 attempt with chemotherapy þ G-CSF displayed the worst outcome of mobilization. 5, 6 In order to improve these results the combination with chemotherapy has been studied in patients with premobilization risk factors. 7 The limit of this approach is based on the fact that some 'predicted poor mobilizers' may be able to yield PBSC without plerixafor. Preliminary data suggest that the socalled 'plerixafor on demand' based on the peripheral blood (PB) CD34 þ cell count at the time hematopoietic recovery after chemotherapy þ G-CSF may be the most efficient and costeffective use of the drug. [8] [9] [10] We report our experience with plerixafor 'on demand' after chemotherapy þ G-CSF in lymphoma patients. Our aim was to evaluate the success rate of this strategy, and to define whether the PB CD34 þ cell count monitoring is a reliable method to select patients who merit plerixafor at the first or subsequent mobilization. Twenty-six patients were treated: 24 non-Hodgkin's lymphomas, 2 Hodgkin's lymphomas. Patient characteristics are listed in Table 1a . Twenty patients (77%) failed a previous mobilization with chemotherapy þ G-CSF: 8 (31%) did not yield PBSC and 12 (46%) yielded o2 Â 10 6 CD34 þ /kg. The remaining six patients (23%) received plerixafor combined with chemotherapy and G-CSF as first-line mobilizing therapy. Patients received high-dose CY or cytarabine-containing chemotherapy as mobilizing cycle, in particular the latter was used in those failing the first attempt with CY. After the end of the chemotherapy regimen (24-72 h), G-CSF was administered at the daily dose of 5 mg/kg. At the time of hematologic recovery (day 8-10 from the last chemotherapy infusion), daily PB CD34 þ cell monitoring was started. The CD34 þ cell count was performed by a singleplatform flow cytometry, using CD34-PE (phycoerythrin) and CD45-FITC (FITC) MoAbs, TruCount fluorospheres (BD, Biosciences, San Jose, CA, USA) in combination with the viability dye, 7-amino actinomycin D to exclude dead cells and the ISHAGE (International Society for Hematotherapy and Graft Engineering) gating strategy. 11 Plerixafor 'on demand' was added at the dose of 240 mg/kg/day on the evening before leukapheresis. The decision to add plerixafor was taken by the treating physicians, who used the following parameters: the timing of leukocyte recovery from chemotherapy, the leukocyte count, the PB CD34 þ cell count at the time of leukocyte recovery and the fold increase of CD34 þ cell count during the following days. These parameters were also identified by the Gruppo Italiano Trapianto di Midollo Osseo group to assess the probability to be a poor mobilizer. 12 Generally, when patients recovered from chemotherapy and the PB CD34 þ cell count was lower than 20/mL the probability of being a 'poor mobilizer' was considered high, therefore plerixafor was added. Moreover, plerixafor was used when we observed a low increase in the PB CD34 þ cell count and a slow hematopoietic recovery. Plerixafor administration was planned in order to reach the minimum target of 2 Â 10 6 CD34 þ /kg. Leukapheresis was started when the neutrophil count was 41000/mL and PB CD34 þ cell count 420/mL.
The results are listed in Table 1b . Twenty-three (88%) patients reached the target. Two failures were observed in a 68-year-old woman with relapsed mantle cell lymphoma and in a 36-year-old woman affected by T-cell lymphoblastic lymphoma, both treated with three previous lines of intensive chemotherapy. In those patients the PB CD34 þ cell count was lower than 10/mL after the first dose of plerixafor, and the treating physician did not continue patient mobilization. Another patient collected only 0.8 Â 10 6 CD34 þ /kg. The median number of collected PBSC after plerixafor was 4.9 Â 10 6 /kg (range, 0.8-12), with 14 (54%) patients collecting X4 Â 10 6 CD34 þ /kg. The median number of G-CSF days before plerixafor was 12 (range, 7-17). The median time from chemotherapy to plerixafor administration was 15 days (range, 12-25). The median number of plerixafor administrations was 1 (range, 1-3), with 73% of patients treated only once and 54% of patients undergoing only one apheresis to reach the target. The median value of leukocytes before plerixafor administration was 9.56 Â 10 9 /L (range, 3.16-32.54) and increased to 22.18 Â 10 9 /L (range, 11.0-55.72) after plerixafor: the median fold increase was 2.31 (range, 1-4.7). The median PB CD34 þ cell count before the first plerixafor administration was 12/mL (range, 0-26) and increased to 51/mL (range, 5-172) after plerixafor: the median fold increase was 4.7 (range, 1-52). Figure 1 showed the results for each patient. As the decision to include plerixafor took into account the increase in CD34 þ cell count after leukocyte recovery, we analyzed the fold increase over the two consecutive days immediately before introduction of plerixafor and we compared the results with the fold increase after plerixafor; the median fold increase in circulating CD34 þ cells over the two consecutive days immediately before the introduction of plerixafor was 2 (range, 0.8-7.9), showing a trend towards significance as compared with the fold increase after plerixafor (P ¼ 0.058).
We compared the outcome of patients at the first or subsequent mobilization to assess whether the former really merited plerixafor, and on the other hand, to evaluate if patients who failed a previous attempt with chemotherapy þ G-CSF could have a worse outcome: the median number of collected PBSC in the 'first-attempt' compared with the 'second-attempt' group was 4.2 Â 10 6 /kg (range, 2-9) vs 5.45 Â 10 6 /kg (range, 0.8-12) (P ¼ 0.144). The median value of PB CD34 þ cell count before the first plerixafor administration was 5/mL (range, 1-15) vs 12/mL (range, 0-26) and increased to 23/mL (range, 7-88) vs 53/mL (range, 5-172) after plerixafor, respectively. The median fold increase of PB CD34 þ cell count was 5.6 (range, 4-14) vs 4.2 (range, 1-52) after the first plerixafor day (P ¼ 0.935). The median day of plerixafor injection from chemotherapy was 19 (range, 12-23) vs 15 (range, 12-22) (P ¼ 0.116). These results did not significantly differ and were in line with previous published data, [8] [9] [10] showing that plerixafor is equally effective at the first and the second mobilization attempt.
Overall, four patients had a leukocyte and PB CD34 þ cell count fold increase higher than three and five after the first plerixafor injection and very high absolute PB CD34 þ cell count. In this small subgroup of patients (15%) the kinetics of recovery and PBSC mobilization suggested that probably plerixafor might have been unnecessary and we could probably reach the target of collection by adding further days of G-CSF. In these patients we were not able to identify any distinct characteristics, as regards leukocyte and PB CD34 þ cell count before plerixafor or timing of plerixafor administration, but all of them underwent mobilization after high-dose aracytin. The studies of high-dose sequential chemotherapy in non-Hodgkin's lymphoma have already shown that 85% of the patients who had failed a previous mobilization with CY were then successfully mobilized by high-dose aracytin. 13 Although these data suggest that we may rescue poor mobilizers just changing the mobilizing chemotherapy, recent data by Tarella and colleagues 14 have demonstrated that patients autografted with PBSC collected after a second course of mobilization with high-dose aracytin had an increased risk of secondary leukemia. The results have been explained by the senescence of the stem cells, as shown by their short telomere length. 15 Overall, these data underline the need of avoiding a second course of mobilization, and further justify the use of plerixafor during the first-line mobilization attempt with CY.
Our conclusions are the following: (i) plerixafor 'on demand' was efficient in most of the lymphoma patients who had a low PB CD34 þ cell count at hematopoietic recovery; (ii) plerixafor 'on demand' after chemotherapy þ G-CSF may be cost-effective, as almost all the patients reached the target after one injection; (iii) patients at the first or subsequent mobilization showed similar results suggesting that plerixafor had the same efficacy in both groups and that PB CD34 þ cell count can be considered the most significant factor correlated to the outcome of mobilization, irrespective of patient history; (iv) owing to the different mobilization cycles, which imply different kinetics of recovery, we were not able to define a cutoff value of leukocyte and PB CD34 þ cell count to add plerixafor. The fact that the fold increase of PB CD34 þ cell count after plerixafor is similar to those reported by the literature, supports our approach based on CD34 þ cell count o20/mL or not increasing after a full hematopoietic recovery. A more precise algorithm is possible only when the same chemotherapy approach is applied, as we have recently suggested in a publication where we have analyzed the kinetics of recovery after high-dose CY. 16 In our experience we had probably 15% of the patients who were able to mobilize PBSC without plerixafor. These patients received high-dose aracytin as a second course of mobilization, which contributed to increase the success of mobilization, but it is not optimal for the stem cell graft. In this perspective, we suggest adding plerixafor during the first mobilization cycle based on the PB CD34 þ cell count and leukocyte recovery, to avoid the toxicity and costs of a second mobilization cycle.
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